V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System

The V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System is engineered to deliver comprehensive multi-modal ultrasound imaging and body fluid analysis for diverse clinical diagnostics. It integrates established ultrasound technology with advanced AI-driven NerveTrack for enhanced anatomical delineation and SonoSync for remote collaboration, aiming to improve diagnostic precision and clinical utility.

The Samsung Medison V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System is a mobile, software-controlled device intended for general-purpose diagnostic ultrasound imaging and body fluid analysis. It acquires and displays ultrasound data using a comprehensive range of imaging modes, including 2D, Color Doppler, Power Doppler, M-mode, Pulsed and Continuous Wave Doppler, Tissue Doppler Imaging and Wave, ElastoScan, 3D/4D, and combined/multi-image modes. The system is designed for use by qualified healthcare professionals across a wide spectrum of clinical applications such as Fetal/Obstetrics, Abdominal, Gynecology, Cardiac (Adult and Pediatric), Muscular-Skeletal, Urology, and Peripheral Vessel imaging, providing tools for anatomical measurements and diagnostic analysis in various healthcare environments. This iteration of the system introduces significant enhancements, including the expanded application of AI-powered NerveTrack Segmentation for improved identification and contour mapping of twelve nerve types and nine surrounding anatomical structures. It incorporates a new TA2-9 transducer, a 27-inch OLED monitor for superior image visualization, and an updated SonoSync feature for remote diagnostic image viewing and review. Non-clinical testing validated the AI's performance, with NerveTrack demonstrating high accuracy (approximately 90.3% for detection and 98.42% for segmentation) and speed, maintaining robustness across various BMI subgroups. The system also features real-time display of mechanical and thermal indices to ensure patient safety during examinations.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of the AI-driven NerveTrack segmentation vary across the twelve different nerve types, particularly in challenging patient anatomies or pathologies?; What specific improvements in image resolution or diagnostic confidence are attributable to the new TA2-9 transducer and the 27-inch OLED monitor, especially in deeper tissue imaging?; What are the bandwidth and latency requirements for optimal performance of the SonoSync remote viewing and review feature, and how does it handle potential network interruptions?; How was the ground truth for NerveTrack's contour segmentation of surrounding structures (bone, blood vessel, muscle, ligament) validated for accuracy across different tissue densities and patient variability?; Are there any comparative studies or data demonstrating the clinical impact of NerveTrack on procedure time, accuracy, or patient outcomes in nerve-related interventions?